rejuvant life tabs

A novel approach to aging – epigenetics and cellular variability

Latest articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...
Rejuvant

Cellular stochasticity and epigenetic drift in aging can not only provide Longevity targets but also give a deeper understanding of the origins of cancer.

Current theories of aging are based strongly on the accumulation of random genetic mutations, and with good reason; however, many aging phenomena remain unexplained, so what is science missing?

Longevity.Technology: Previously epigenetic links to aging have been explained as casual, yet Jean-Pascal Capp and Frédéric Thomas reconsider this [1]. While genetics focuses on genes encoded in DNA, epigenetics allows gene expression control through chemical tags, such as histone and DNA methylation. With age, an epigenetic drift occurs, where stochastic – a fancy word for random – methylation events lead to a diverging epigenome.

A diverging epigenome is one of the factors leading to more variability between cells, correlated to both in aging and cancer. The Landau group in the Dana-Farber Cancer Institute in Boston, found that highly methylated promoters in chronic lymphocytic leukaemia leads to high cell-to-cell expression of the corresponding gene [2]. This supports the argument that epigenetic methylation correlates more than casually to cellular variation.

DNA damage has many causes, but nature has developed intricate biological repair systems to mend the breakage or remove the affected cells. With age, these restoration machines falter, leading to a cause for further epigenomic variation. These epimutations deviate from the template for healthy gene expression, resulting in aging and cancer phenotypes.

Tissue‐disruption‐induced cellular stochasticity and epigenetic drift: Common origins of aging
Illustration of adherent mammalian cells. Source: Toulouse Biotechnology Institute, Bio & Chemical Engineering

Other factors affecting cell heterogeneity include cell identity and tissue type. It has been found that different tissues and organs age at a different rate. It is proposed that this is in fact an evolutionary adaptation, whereby organs with a higher risk of cancer age more slowly, thus decreasing cell variation and probability of cancer.

Elevant

This, along with cell-to-cell variation and origins of cancer can potentially be explained by Thomas and Capp’s novel aging theory – Tissue Disruption-induced cellular Stochasticity (TiDiS). As cells develop, they tend towards homogeneity through differentiation. Chromatin is epigenetically programmed to become less accessible, leaving only genes that need to be expressed for the specific cell type. Yet with natural epigenomic variation, some cells regain their stem-like properties.

Most cells return to their specialised form by taking cues from their environment in order to maximise nutrition resource allocation and to achieve optimal proliferation. Some cells lose the ability to do so, failing to set up cellular interactions crucial for differentiation and thus become cancerous stem cells (CSC) – key in TiDiS. Interestingly, this theory doesn’t require a faulty genetic framework, which may explain why an oncogenic event does not necessarily develop into a malignant cancer.

 


 

“More research with cell-to-cell interactions and epigenetic markers must be conducted for solid therapeutic applications…”

 


 

 

Parallels between cancer and aging have been outlined in numerous reviews [3]. However, here we find a hypothesis of how cellular variation due to age can lead to stochastic changes increasing cancer risk. More research with cell-to-cell interactions and epigenetic markers must be conducted for solid therapeutic applications.

Single-cell analyses can reveal cellular interactions, while more systemic analyses can reveal ligand-receptor pairs without the need for previous knowledge. Fluorescent microscopy can further provide understanding of localisation of key biomarkers for aging. Diseased and healthy aging tissues must be studied and compared, yet samples of the later are hard to come by.

Elevant

What Thomas’ team illustrate is an undeniable link between epigenetic stochasticity and cellular interactions with Longevity and cancer. Longevity and age-related diseases are in need of a deeper understanding of underlying mechanisms – a new direction focusing on cell heterogeneity and stochasticity may just be the answer to a therapeutic approach to aging and cancer.

[1] https://onlinelibrary.wiley.com/doi/abs/10.1002/bies.202000140
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302418/
[3] https://go.nature.com/35ICwbF

Image courtesy of: Toulouse Biotechnology Institute, Bio & Chemical Engineering
Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

Targeting mitochondria to beat hair loss and skin wrinkles

Yuva Biosciences gears up for human trials of cosmeceutical treatments that target mitochondrial dysfunction. With an initial focus on developing cosmeceuticals, US start-up Yuva Biosciences...

HitGen and BioAge progress drug discovery collaboration

Companies announce research progress in DNA-encoded library-based drug discovery research collaboration. Shanghai Stock Exchange-listed biotech HitGen, Inc announced important research progress in a collaboration with...

Nerve regeneration tech targets Alzheimer’s and Nasdaq

NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve regeneration technology, Canadian biotech NervGen...

ITP lifespan extension study: more NAD+ research

ITP lifespan extension study brings mixed bag of results for longevity drugs. The long-awaited results of the National Institute on Aging Interventions Testing Program's look...
Supps report ad middle